News

Promising Phase 2 Data for BDTX-1535 in NSCLC Patients

Promising Phase 2 Data for BDTX-1535 in NSCLC Patients

Black Diamond Therapeutics Shares Exciting Phase 2 Results

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), an innovative clinical-stage company in oncology, has recently released its initial findings from a Phase 2 trial that assessed the effectiveness of BDTX-1535. This novel therapy specifically targets mutations found in patients with recurrent epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC).

Key Clinical Insights

The trial revealed that a daily dose of 200 mg of BDTX-1535 is well-tolerated with no unexpected safety concerns. Impressively, the treatment achieved a preliminary objective response rate (ORR) of 42% among 19 patients, all of whom had on-target resistance EGFR mutations.

Notable Durability and Ongoing Treatments

Within those who showed a partial response, three patients demonstrated exceptional durability, with their response times averaging around 8 months. At this moment, 14 of the 19 enrolled patients are still receiving treatment.

Responding to a Critical Need in Patient Care

Dr. Sergey Yurasov, the Chief Medical Officer at Black Diamond Therapeutics, highlighted the importance of these results, pointing out that many patients struggle with resistance to current therapies like osimertinib. He underlined the potential of BDTX-1535 to provide extended therapeutic responses for these patients.

The Urgent Need for New Treatment Options

Dr. Danny Nguyen commented on the limited available treatments for patients dealing with recurrent EGFRm NSCLC. He expressed his enthusiasm for the promising data from BDTX-1535 and stressed the urgent necessity for effective and well-tolerated therapies.

A Closer Look at the Phase 2 Trial

The Phase 2 study began by enrolling patients with both non-classical EGFR mutations and those with C797S resistance mutations. After a thorough safety evaluation, patients were administered either 100 mg or 200 mg of BDTX-1535 daily. The results were optimistic, showing a 36% ORR among the 22 patients evaluated for response.

Safety and Tolerability Reports

The safety profile appeared to be generally positive, with most adverse events ranging from mild to moderate. The most commonly reported side effects included rash and diarrhea, with no serious complications occurring in those receiving the higher 200 mg dose.

Future Trials and Expectations on the Horizon

The company is actively pursuing trials in both second- and third-line patient cohorts, as well as in first-line settings for those with non-classical mutations. Initial findings and regulatory insights are expected soon, with more comprehensive data anticipated to be released in the first quarter of next year.

What is BDTX-1535?

BDTX-1535 is an oral, brain-penetrating fourth-generation tyrosine kinase inhibitor (TKI) designed to target various oncogenic EGFR mutations prevalent in non-small cell lung cancer. Its special formulation allows it to interact with mutations that have developed resistance to previous treatments, making it an important candidate in the ongoing fight against advanced lung cancer.

Current Trials and Research Efforts

There are two major clinical programs underway: BDTX-1535 and BDTX-4933, which targets critical mutations across various solid tumors. The potential of BDTX-1535 is being investigated in separate trials, aimed at helping patients who have had limited success with existing therapies.

Frequently Asked Questions

What is the main purpose of BDTX-1535?

BDTX-1535 targets specific mutations in the EGFR associated with non-small cell lung cancer, particularly in patients who have shown resistance to standard treatments.

How well is BDTX-1535 tolerated by patients?

Preliminary findings indicate that BDTX-1535 is well-tolerated, with adverse events mostly being mild or moderate.

What were the response rates observed in the Phase 2 trial?

The trial reported a preliminary objective response rate (ORR) of 42% for patients with on-target resistance mutations.

What is the anticipated timeline for further data release?

We expect more detailed results and regulatory feedback from the ongoing trials in the first quarter of next year.

Why is there a need for therapies like BDTX-1535?

Current treatment options for recurrent EGFRm NSCLC are limited, often relying on chemotherapy that may not be effective and can cause serious side effects, highlighting the need for new, effective therapeutic alternatives.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Illumina's Virtual Cell Win Raises Bigger AI Stakes

Updated Category News Views 76

A blind prediction contest is a useful place to separate glossy AI talk from actual biology. Illumina's BioInsight AI Lab took first place in Arc Institute's 2026 Virtual Cell Challenge, outperforming roughly 1,500 competitors on predictions of how cells would react when genes were knocked down. That is not a quarterly revenue number, and nobody should pretend otherwise....

Continue Reading
Botanica’s Illuminations Carries More Than Holiday Glow

Updated Category News Views 106

Two million lights are doing more than brightening up a few winter evenings in Wichita. Illuminations at Botanica returns from November 23, 2026, through January 2, 2027, and the pleasant part of this story is that the spectacle has a practical backbone: it is Botanica’s largest fundraiser. For a garden nonprofit, that matters a whole lot more than another shiny...

Continue Reading
Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 208

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
Liquidity Services Faces a Brutal Revenue Reality Check

Updated Category News Views 33

A 19.17% opening haircut is the market ringing the fire alarm, not politely clearing its throat. Liquidity Services reported fiscal fourth-quarter revenue of $106.4 million, roughly 10% below the prior-year quarter, and shareholders got hit hard on November 19, 2026. That reaction is ugly, but it is not mysterious. When a company built around moving surplus inventory...

Continue Reading
Huawei's Financial AI Push Targets Scale, Not Demos

Updated Category News Views 79

Banking AI has reached the point where a clever chatbot barely moves the needle. Huawei's message at Singapore FinTech Festival 2026 was aimed squarely at that harder, more expensive problem: turning AI from a scattered pilot project into machinery a financial institution can operate, govern, repeat, and improve without handing over its crown jewels. Ownership Is the...

Continue Reading
DPR’s Parent Benefits Signal a Tougher Labor Market

Updated Category News Views 34

Concrete Schedules Do Not Bend Easily A jobsite does not care that daycare closes at 6 p.m., and that is exactly why DPR Construction’s latest workplace recognition deserves a closer look. The privately held, employee-owned contractor landed at No. 29 among large companies on the 2026 Fortune Best Workplaces for Parents list. It is not a quarterly earnings event, and...

Continue Reading
Movement Elevates a Longtime Insider as Its New CEO

Updated Category News Views 87

Chalk dust rarely makes headlines, yet this is the sort of leadership change that can decide whether a consumer brand keeps its footing. Movement Climbing, Yoga and Fitness named Ryan Sewell chief executive officer effective November 18, 2026, with Anne-Worley Moelter moving into the chairperson role. It is a conspicuously internal handoff: Sewell started at the Boulder...

Continue Reading
Global-E Faces Fresh Scrutiny After Muted Quarterly Outlook

Updated Category News Views 39

A guidance bump that barely clears the curb can still wreck a stock. That is the unpleasant read-through from Global-E Online's third-quarter 2026 report: revenue guidance went higher, but not high enough to persuade investors that the business was pulling away from expectations. Shares fell after the release, and a securities-law investigation announced November 19 has...

Continue Reading
Arizona's Dry Climate Puts Scalp Health Under Stress

Updated Category News Views 16

Desert weather is unforgiving, and apparently the scalp does not get a pass. In a Nov. 20, 2026 discussion, Scottsdale and Tucson hair-restoration physician Dr. Sharon A. Keene frames Arizona hair concerns around something easy to overlook: the condition of the skin beneath the hair. That is a more sensible starting point than treating every strand in the shower like it...

Continue Reading
Chipotle's Thanksgiving BOGO Tests Loyalty Muscle Again

Updated Category News Views 35

Thanksgiving Eve is a peculiar little battlefield for restaurant chains: everybody wants the reunion crowd, nobody wants to give away the register. Chipotle is stepping back into it on Wednesday, November 25, with its Back Home BOGO for Rewards members from 5 to 9 p.m. local time at participating U.S. restaurants. Buy an entrée in person, scan the Rewards account, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Westpac's CEO Calls for Enhanced Social Media Fraud Measures

Updated Category News Views 140

Westpac's Urgent Plea for Enhanced Fraud Prevention Westpac Banking Corp's CEO has made a significant call for social media companies, including Meta Platforms, to take a more proactive role in fighting online financial fraud. With an alarming rise in scams targeting consumers, this appeal highlights the urgent need for a united front against fraudulent activities online....

Continue Reading
Empowering Veterans: Bombardier's Commitment to Career Success

Updated Category News Views 170

Empowering Veterans Through Partnership with the Army Today, Bombardier proudly announces its partnership with the U.S. Army via the Partnership for Your Success (PaYS) Program. This initiative is designed to connect service members with valuable civilian career opportunities, ensuring they receive guaranteed job interviews with participating employers. This strategic...

Continue Reading
AWH Faces Market Challenges with Stock at Record Low

Updated Category News Views 107

AWH Stock Experiences Significant Decline AWH stock has recently dropped to a concerning 52-week low of $0.38, reflecting the tough market conditions. The dip in stock price highlights the company’s struggles, with its market capitalization now at a mere $6.5 million. Over the past year, the stock has lost approximately 90.68% of its value, showcasing a substantial...

Continue Reading
Vimeo's Q3 2024 Financial Insights and Future Outlook

Updated Category News Views 370

Vimeo Posts Third Quarter 2024 Financial Update Vimeo recently shared its financial snapshot for the third quarter of 2024, showcasing the company's growth trajectory and key achievements. The shareholder letter is now available on the investor relations section of their website, allowing stakeholders to delve into the details. This transparency is vital for maintaining...

Continue Reading
Implantica's Year-End Report Highlights RefluxStop Progress

Updated Category News Views 165

Implantica's Year-End Report: Driving Forward with Innovation Implantica has made significant strides in the healthcare sector, particularly with its innovative product, RefluxStop™, which aims to transform how gastroesophageal reflux is treated. This year-end report presents a comprehensive overview of the company's achievements for the year. RefluxStop™ FDA...

Continue Reading